Main menu button

News

Research Update Kancera, Q4 2022: Start of cancer trial expected shortly
15 Mar 2023
Research Update Kancera, Q4 2022: Start of cancer trial expected shortly
Equity Research
Research Update InCoax, Q4 2022: Positive follow-up orders from US operator
13 Mar 2023
Research Update InCoax, Q4 2022: Positive follow-up orders from US operator
Equity Research InCoax
First Impression InCoax, Q4 2022: Better than expected revenues, but low gross margin
10 Mar 2023
First Impression InCoax, Q4 2022: Better than expected revenues, but low gross margin
Equity Research InCoax
Carlsquare weekly market letter: Big Evening Star in S&P 500
08 Mar 2023
Carlsquare weekly market letter: Big Evening Star in S&P 500
Equity Research Carlsquare
Research update Zinzino, Q4 2022: Profit growth in the cards for 2023
06 Mar 2023
Research update Zinzino, Q4 2022: Profit growth in the cards for 2023
Equity Research Zinzino
Research update Risk Intelligence, Q4 2022: Large global customers can give a boost
06 Mar 2023
Research update Risk Intelligence, Q4 2022: Large global customers can give a boost
Equity Research Risk Intelligence
Carlsquare weekly market letter: Can Junk lead the way?
01 Mar 2023
Carlsquare weekly market letter: Can Junk lead the way?
Equity Research Carlsquare
Research update ALM Equity: Write-downs in associates affect results
28 Feb 2023
Research update ALM Equity: Write-downs in associates affect results
Equity Research ALM Equity
First impressions Zinzino, Q4 2022: Again, profitability above our expectations
28 Feb 2023
First impressions Zinzino, Q4 2022: Again, profitability above our expectations
Equity Research Zinzino
Research Update SBB i Norden Q4 2022: Better earnings outweigh lower NAV
24 Feb 2023
Research Update SBB i Norden Q4 2022: Better earnings outweigh lower NAV
Equity Research SBB i Norden
First Impression SBB i Norden, Q4 2022: Better earnings capacity than expected
23 Feb 2023
First Impression SBB i Norden, Q4 2022: Better earnings capacity than expected
Equity Research SBB i Norden
First impression Risk Intelligence, Q4 2022: Mixed outcome in comparison to our adjusted estimates
22 Feb 2023
First impression Risk Intelligence, Q4 2022: Mixed outcome in comparison to our adjusted estimates
Equity Research Risk Intelligence
First impression ALM Equity, Q4 2022: Asset write downs impact results
22 Feb 2023
First impression ALM Equity, Q4 2022: Asset write downs impact results
Equity Research ALM Equity
Carlsquare weekly market letter: Better numbers push stocks lower, thanks to the Fed
22 Feb 2023
Carlsquare weekly market letter: Better numbers push stocks lower, thanks to the Fed
Equity Research Carlsquare
Carlsquare Equity Research Nordic Life Science sector update
20 Feb 2023
Carlsquare Equity Research Nordic Life Science sector update
Equity Research Abera Bioscience
Research Update Ecoclime Q4 2022: A very strong quarter for Evertherm
20 Feb 2023
Research Update Ecoclime Q4 2022: A very strong quarter for Evertherm
Equity Research
Update HANZA Q4 2022: Stars still aligned for expansion
17 Feb 2023
Update HANZA Q4 2022: Stars still aligned for expansion
Equity Research Hanza
First Impression Ecoclime Q4 2022: Better than expected revenue growth
16 Feb 2023
First Impression Ecoclime Q4 2022: Better than expected revenue growth
Equity Research
Carlsquare successfully advised Keran Group in buying a majority stake in YS Energies Marine Developpement
15 Feb 2023
Carlsquare successfully advised Keran Group in buying a majority stake in YS Energies Marine Developpement
Deal News
Carlsquare weekly market letter: Is SEK at a breakpoint and what does it imply for the stock market?
15 Feb 2023
Carlsquare weekly market letter: Is SEK at a breakpoint and what does it imply for the stock market?
Equity Research Carlsquare